(179 days)
Not Found
No
The device description and summary of performance studies focus on a physical implant and injector, with no mention of software, algorithms, or data processing that would indicate AI/ML. The "Mentions AI, DNN, or ML" and "Mentions image processing" fields are explicitly marked as "Not Found".
Yes
The device is indicated for the management of refractory glaucomas and creates a permanent channel to allow aqueous flow, which directly treats the condition.
No
The XEN Glaucoma Treatment System is described as a treatment device (stent and injector for glaucoma management) rather than a device used for diagnosis.
No
The device description clearly states it consists of a physical gel stent and an injector, which are hardware components.
Based on the provided information, the XEN Glaucoma Treatment System is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is for the management of refractory glaucomas by creating a channel for aqueous flow. This is a surgical intervention performed in vivo (within the body) to treat a condition.
- Device Description: The device is a physical implant (gel stent) and an injector used to place the implant. It is designed to function within the body.
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the body to provide information about a person's health. The XEN system does not involve the analysis of specimens outside the body.
The XEN Glaucoma Treatment System is a surgical implant used to treat glaucoma directly within the patient's eye.
N/A
Intended Use / Indications for Use
The XEN Glaucoma Treatment System is indicated for the management of refractory glaucomas, including cases where previous surgical treatment has failed, cases of primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.
Product codes
KYF
Device Description
The XEN Glaucoma Treatment System consists of the XEN45 Gel Stent preloaded into the XEN Injector. The XEN45 Gel Stent is composed of a gelatin derived from porcine dermis, formed into a tube, and then cross-linked with glutaraldehyde. The inside diameter of the tube is approximately 45 um, its outside diameter is approximately 150 um, and it has a length of approximately 6 mm. The XEN45 Gel Stent creates a permanent channel through the sclera allowing aqueous flow from the anterior chamber to the subconjunctival space.
The XEN45 Gel Stent is preloaded into an injector designed to place the XEN45 Gel Stent in the intended position. The injector with the preloaded implant is sterilized via gamma irradiation and is provided sterile. The injector is discarded after a one-time use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Bench Testing:
The nonclinical bench testing conducted on the XEN Glaucoma Treatment System included design verification and functional product testing, sterilization validation, packaging and shelf life testing, and biocompatibility testing. Results of the nonclinical testing demonstrate that the XEN Glaucoma Treatment System meets the defined specifications.
Design Verification and Functional Product Testing: The XEN45 Gel Stent and the XEN injector were evaluated to verify that the design output met the original design input and intent. This testing was based on tests described in ANSI Z80.27, Implantable Glaucoma Devices. The results establish that the XEN Glaucoma Treatment System meets the design intent and complies with the applicable requirements.
Sterilization Validation: The gamma irradiation sterilization method was validated using the VDmax 26 method described in BS EN ISO 11137-1:2015 and BS EN ISO 11137-2:2015. Validation results demonstrate that a minimum exposure dose of 25 kGy has been substantiated for the routine sterilization of the XEN Glaucoma Treatment System to provide a 10-6 sterility assurance level (SAL).
Packaging and Shelf Life Testing: The XEN Glaucoma Treatment System is labeled with an expiration date of 3 years. The shelf life study evaluated the functional performance of the XEN45 Gel Stent and the XEN injector, as well as the packaging integrity of the tray sealed with the Tyvek lid. Additional testing was completed to evaluate the impact of environmental conditioning and distribution factors. Test results confirm that the XEN45 Gel Stent and the XEN injector meet their functional requirements and the sterile barrier (package integrity) remains intact after simulated distribution and aging. This testing provides the justification for the 3-year shelf life and the maintenance of the sterile barrier.
Biocompatibility Testing: Biocompatibility of the final finished XEN Glaucoma Treatment System was demonstrated through testing in accordance with BS EN ISO 10993-1 "Biological evaluation of medical devices, Part 1: Evaluation and testing within a risk management process". Testing was performed for the Gel Stent material and for the injector components that have contact with the patient or the Gel Stent. All testing demonstrated that the device materials have an acceptable biocompatibility profile. See table provided in document for specific tests and results.
Clinical Evidence Supporting Substantial Equivalence: A prospective, multi-center, single arm, open-label, clinical trial was conducted at 12 sites in the U.S. to evaluate the safety and effectiveness of the XEN45 Gel Stent in refractory glaucoma subjects where previous filtering or cilioablative procedures failed or IOP was unresponsive to maximally tolerated medical therapy. Sixty-five subjects were implanted with the XEN45 Gel Stent and 18-month data were collected for safety.
Effectiveness:
- 76.3% of subjects were able to obtain a 12-month mean diurnal IOP reduction of > 20% from baseline on the same or fewer IOP-lowering medications.
- The mean diurnal IOP reduction from baseline at the 12-month visit was -6.4 ± 1.1 (SE).
- The mean diurnal IOP at baseline for all subjects (n=65) was 25.1 (+ 3.7) mmHg and the mean diurnal IOP at 12 months (using only observed data) for the 52 subjects who were seen at the 12-month visit was 15.9 (± 5.2) mmHg.
- The mean number of IOP-lowering medications at baseline was 3.5 (± 1.0) compared to 1.7 (± 1.5) medications at the 12-month visit (based on observed data).
Safety: The most common adverse events reported prior to and including the 12-month visit were: additional glaucoma surgery with or without device explant, hypotony defined as
§ 886.3920 Aqueous shunt.
(a)
Identification. An aqueous shunt is an implantable device intended to reduce intraocular pressure in the anterior chamber of the eye in patients with neovascular glaucoma or with glaucoma when medical and conventional surgical treatments have failed.(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Devices—Part I: Evaluation and Testing,’ ”
(2) “510(k) Sterility Review Guidance of 2/12/90 (K90-1),” and
(3) “Aqueous Shunts—510(k) Submissions.”
0
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with three lines forming its body and wings. The eagle is positioned to the right of a circular emblem that contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 21, 2016
Allergan, Inc. Ms. Barbara Niksch Executive Director, Clinical Affairs 26970 Aliso Vieio Parkwav, Suite 200 Aliso Viejo, CA 92656
Re: K161457
Trade/Device Name: Xen Glaucoma Treatment System Regulation Number: 21 CFR 886.3920 Regulation Name: Aqueous Shunt Regulatory Class: Class II Product Code: KYF Dated: October 7, 2016 Received: October 11, 2016
Dear Ms. Niksch:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801): medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Kesia Alexander
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K161457
Device Name Xen Glaucoma Treatment System
Indications for Use (Describe)
The XEN Glaucoma Treatment Systemis indicated for the management of refractory glaucomas, including cases where previous surgical treatment has failed, cases of primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ---------------------------------------------- | --------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
This 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92.
| I. SUBMITTER | Allergan, Inc.
2525 Dupont Drive
Mail Code T2-6L
Irvine, CA 92612 |
|------------------------|-----------------------------------------------------------------------------------------------|
| Contact Person: | Barbara A. Niksch
Executive Director, Clinical Affairs
Allergan, Inc.
(714) 246-6914 |
| Date Summary Prepared: | November 16, 2016 |
| II. DEVICE | |
| Trade Name: | XEN Glaucoma Treatment System |
| Common Name: | Glaucoma Implant |
Classification Name: Aqueous shunt (21 CFR 886.3920)
Class II (special controls)
Device Product Code: KYF ("Implant, Eye Valve")
III. PREDICATE DEVICES
Device Class:
- Ahmed Glaucoma Valve Implant, Model S2 (K925636) .
- EX-PRESS Glaucoma Filtration Device (formerly referred to as the Ex-Press Mini Glaucoma . Implant (K012852))
4
IV. DEVICE DESCRIPTION
The XEN Glaucoma Treatment System consists of the XEN45 Gel Stent preloaded into the XEN Injector. The XEN45 Gel Stent is composed of a gelatin derived from porcine dermis, formed into a tube, and then cross-linked with glutaraldehyde. The inside diameter of the tube is approximately 45 um, its outside diameter is approximately 150 um, and it has a length of approximately 6 mm. The XEN45 Gel Stent creates a permanent channel through the sclera allowing aqueous flow from the anterior chamber to the subconjunctival space.
The XEN45 Gel Stent is preloaded into an injector designed to place the XEN45 Gel Stent in the intended position. The injector with the preloaded implant is sterilized via gamma irradiation and is provided sterile. The injector is discarded after a one-time use.
V. INTENDED USE
The XEN Glaucoma Treatment System has the same intended use as the predicates and all other devices regulated within the generic type of device known as aqueous shunts in accordance with 21 CFR 886.3920. The device is a prescription (Rx) device that is intended to be permanently implanted to reduce intraocular pressure for the management of glaucoma. The XEN Glaucoma Treatment System will bear the following indications for use statement:
The XEN Glaucoma Treatment System is indicated for the management of refractory glaucomas, including cases where previous surgical treatment has failed, cases of primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.
COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE VI. PREDICATE DEVICES
The technological characteristics of the XEN Glaucoma Treatment System, the Ahmed Glaucoma Valve and the EX-PRESS Glaucoma Filtration Device are similar. Furthermore, the differences in technological characteristics that exist between the XEN Glaucoma Treatment System and both legally marketed predicate devices do not raise different questions of safety and effectiveness.
5
Comparison of the XEN Glaucoma Treatment System and the Predicate Devices
| | XEN Glaucoma
Treatment System | Ahmed Glaucoma Valve | EX-PRESS Glaucoma
Filtration Device |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | To be permanently
implanted to reduce
intraocular pressure for the
management of glaucoma | To be permanently
implanted to reduce
intraocular pressure for the
management of glaucoma | To be permanently
implanted to reduce
intraocular pressure for the
management of glaucoma |
| Indications for Use | The XEN Glaucoma
Treatment System is
indicated for the
management of refractory
glaucomas, including cases
where previous surgical
treatment has failed, cases
of primary open angle
glaucoma, and
pseudoexfoliative or
pigmentary glaucoma with
open angles that are
unresponsive to maximum
tolerated medical therapy. | The Ahmed Glaucoma
Valve is indicated for the
management of refractory
glaucomas, where previous
surgical treatment has
failed, or by experience is
known not to provide
satisfactory results. Such
refractory glaucomas can
include neovascular
glaucoma, primary open
angle glaucoma
unresponsive to medication,
congenital or infantile
glaucoma and refractory
glaucomas resulting from
aphakia or uveitis. | The EX-PRESS Glaucoma
Filtration Device is
intended to reduce
intraocular pressure in
glaucoma patients where
medical and conventional
surgical treatments have
failed. |
| Rx or OTC | Rx | Rx | Rx |
| Permanent Implant | Yes | Yes | Yes |
| Mechanism of Action | Creates an outflow pathway
from the anterior chamber
to the subconjunctival
space through which
aqueous humor can flow
resulting in a conjunctival
bleb. | Creates a channel via a tube
for aqueous flow from the
anterior chamber to the
subconjunctival space
resulting in a bleb formed
within the encapsulated
polypropylene plate. | Creates an outflow pathway
from the anterior chamber
to the subconjunctival
space through which
aqueous humor can flow
resulting in a conjunctival
bleb. |
| Method of Insertion | Via a pre-loaded XEN
Injector | Manual insertion with
Class I surgical instruments | Via a pre-loaded
EX-PRESS Delivery
System (EDS) |
| Design | Single piece tube | Drainage tube and a
valve/reservoir body | Single piece tube |
| Material | Porcine collagen/gelatin | Silicone drainage tube
Polypropylene
valve/reservoir body
Silicone elastomer valve
membrane | Stainless steel |
| | XEN Glaucoma
Treatment System | Ahmed Glaucoma Valve | EX-PRESS Glaucoma
Filtration Device |
| Size
(nominal dimensions) | XEN45 Gel Stent dry
dimensions:
6 mm length
45 microns inner diameter
150 microns outer diameter | Implant:
13 mm width, 16 mm
length, 1.9 mm height
Tube: 0.317 mm inner
diameter (317 microns) and
0.635 mm outer diameter
(635 microns) | Single piece tube: 2-3 mm
length and 0.4 mm (400
microns) outer diameter
Models R30 and R50 were
originally cleared and have
different flow
characteristics created by
different wire diameters
welded into the device.
The higher the number, the
lower the resistance. The
"30" and "50" designators
refer to the size of the inner
diameter in microns. |
| Sterile, Single-Use | Yes | Yes | Yes |
| Sterilization Method | Gamma | Gamma | Gamma |
6
VII. PERFORMANCE DATA
Bench Testing A.
The nonclinical bench testing conducted on the XEN Glaucoma Treatment System included design verification and functional product testing, sterilization validation, packaging and shelf life testing, and biocompatibility testing. Results of the nonclinical testing demonstrate that the XEN Glaucoma Treatment System meets the defined specifications.
Design Verification and Functional Product Testing:
The XEN45 Gel Stent and the XEN injector were evaluated to verify that the design output met the original design input and intent. This testing was based on tests described in ANSI Z80.27, Implantable Glaucoma Devices. The results establish that the XEN Glaucoma Treatment System meets the design intent and complies with the applicable requirements.
Sterilization Validation:
The gamma irradiation sterilization method was validated using the VDmas 26 method described in BS EN ISO 11137-1:2015 and BS EN ISO 11137-2:2015. Validation results demonstrate that a minimum exposure dose of 25 kGy has been substantiated for the routine sterilization of the XEN Glaucoma Treatment System to provide a 10-6 sterility assurance level (SAL).
7
Packaging and Shelf Life Testing:
The XEN Glaucoma Treatment System is labeled with an expiration date of 3 years. The shelf life study evaluated the functional performance of the XEN45 Gel Stent and the XEN injector, as well as the packaging integrity of the tray sealed with the Tyvek lid. Additional testing was completed to evaluate the impact of environmental conditioning and distribution factors. Test results confirm that the XEN45 Gel Stent and the XEN injector meet their functional requirements and the sterile barrier (package integrity) remains intact after simulated distribution and aging. This testing provides the justification for the 3-year shelf life and the maintenance of the sterile barrier.
Biocompatibility Testing
Biocompatibility of the final finished XEN Glaucoma Treatment System was demonstrated through testing in accordance with BS EN ISO 10993-1 "Biological evaluation of medical devices, Part 1: Evaluation and testing within a risk management process" (refer to the table below for a listing of all tests performed). Testing was performed for the Gel Stent material and for the injector components that have contact with the patient or the Gel Stent. All testing demonstrated that the device materials have an acceptable biocompatibility profile.
| Test | Results |
|---|---|
| Gel Stent Material Testing | |
| Cytotoxicity (MEM Elution) | Non-cytotoxic |
| Guinea Pig Maximization Sensitization | Non-irritant compared to negative control |
| Acute Systemic Toxicity (Mouse) | Non-toxic |
| Intraocular Irritation (Rabbit) | No evidence of irritation |
| Bacterial Mutagenicity – Ames Assay | Non-mutagenic |
| 4 Week Intramuscular Implant (Rabbit) | Non-irritant compared to USP negative |
| control | |
| Direct Contact Cytotoxicity | Non-cytotoxic |
| Immunogenicity (Mouse) | Non-immunogenic |
| Injector Component Testing | |
| Cytotoxicity (MEM Elution) | Non-cytotoxic |
| Guinea Pig Maximization Sensitization | Non-irritant compared to negative control |
| Intraocular Irritation (Rabbit) | No evidence of irritation |
Listing of All Biocompatibility Tests Performed on All Patient Contacting Materials
B. Clinical Evidence Supporting Substantial Equivalence
A prospective, multi-center, single arm, open-label, clinical trial was conducted at 12 sites in the U.S. to evaluate the safety and effectiveness of the XEN45 Gel Stent in refractory glaucoma
8
subjects where previous filtering or cilioablative procedures failed or IOP was unresponsive to maximally tolerated medical therapy . Sixty-five subjects were implanted with the XEN45 Gel Stent and 18-month data were collected for safety.
The safety and effectiveness data from this clinical study establish, in the context of the publicly available data for the predicate devices, that there is no difference with respect to substantial equivalence in safety and effectiveness outcomes between the XEN45 Gel Stent and legally marketed predicate devices, confirming that the XEN45 Gel Stent is as safe and effective as the predicate devices.
Effectiveness
The results for the specified effectiveness outcomes (based on multiple imputations) are as follows:
- 76.3% of subjects were able to obtain a 12-month mean diurnal IOP reduction of . > 20% from baseline on the same or fewer IOP-lowering medications.
- The mean diurnal IOP reduction from baseline at the 12-month visit was -6.4 ± 1.1 (SE). .
The results of additional analyses are as follows:
- The mean diurnal IOP at baseline for all subjects (n=65) was 25.1 (+ 3.7) mmHg and the . mean diurnal IOP at 12 months (using only observed data) for the 52 subjects who were seen at the 12-month visit was 15.9 (± 5.2) mmHg.
- The mean number of IOP-lowering medications at baseline was 3.5 (± 1.0) compared to . 1.7 (± 1.5) medications at the 12-month visit (based on observed data)
The effectiveness data, when compared to the publicly available data for the predicate devices, demonstrate that the XEN Glaucoma Treatment System lowers IOP to similar levels as the predicate devices without raising different questions regarding effectiveness.
Safety
The most common adverse events reported prior to and including the 12-month visit were: additional glaucoma surgery with or without device explant, hypotony defined as